Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Nature Communications|December 4, 2021
Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaGeorgia Zoumpoulidou, Carlos Alvarez-Mendoza, Caterina Mancusi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.
Molecular Oncology|October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitorSteven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Oncogene|June 1, 2019
Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerSteve Wagner, Georgios Vlachogiannis, Alexis De Haven Brandon, et al.
Oncogene|October 25, 2018
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerSteve Wagner, Georgios Vlachogiannis, Alexis De Haven Brandon, et al.
Pageof 2